cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Allogene Therapeutics Inc
14 own
13 watching
Current Price
$2.35
$-0.19
(-7.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
558.27M
52-Week High
52-Week High
6.05000
52-Week Low
52-Week Low
2.23000
Average Volume
Average Volume
2.57M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization558.27M
icon52-Week High6.05000
icon52-Week Low2.23000
iconAverage Volume2.57M
iconDividend Yield--
iconP/E Ratio--
What does the Allogene Therapeutics Inc do?
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company has a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to deliver intracellular RNA or DNA into lymphocytes, including T cells. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More
How much money does Allogene Therapeutics Inc make?
News & Events about Allogene Therapeutics Inc.
Benzinga
12 months ago
Thursday,Allogene Therapeutics Inc(NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T nave patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) treated with the Alloy manufacturing process material across different&nbs Latest ...
Globe Newswire
1 year ago
Presentation Includes Data on All 33 CAR T-Nave Patients Treated with the Alloy Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose RegimenResults Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete Responses Comparable...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer,today announced it will present updated data from the Phase 1 ALPHA/ALPHA2...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO Research Report), with a pri... In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO &#8211...
Globe Newswire
1 year ago
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle Infusion of ALLO-316 Demonstrates Promising Anti-Tumor Activity in CD70 Expressing RCC Three of 10 ...
Frequently Asked Questions
Frequently Asked Questions
What is Allogene Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Allogene Therapeutics Inc shares?
plus_minus_icon
How can I buy Allogene Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Allogene Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Allogene Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Allogene Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Allogene Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Allogene Therapeutics Inc?
plus_minus_icon
What percentage is Allogene Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Allogene Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.35
$-0.19
(-7.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00